# NCT02013648 (NCT02013648)

> Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02013648
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: University of Ulm
- Conditions: Acute Myeloid Leukemia (AML)
- Interventions: Dasatinib; Cytarabine; Daunorubicin; Idarubicin
- Enrollment: 204
- Primary outcome: Event-free Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 15
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02013648

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02013648", "email": "<work email>"}; the inbox owner confirms by the emailed link.